11630 SW 97 Street, Miami, Florida 33176, US
Advertising Driven Press Release Distribution
Advertising Driven Press Release Distribution
ACE Inhibitors with Thiazides Drugs Market Overview
The ACE Inhibitors with Thiazides Drugs Market size is estimated to reach $9.1 billion by 2027. Furthermore, it is poised to grow at a CAGR of 2.7% over the forecast period of 2022-2027. ACE is an acronym for Angiotensin-converting enzyme. The following angiotensin enzyme is responsible to lower the blood pressure of a person by relaxing the veins and arteries. It works by blocking the production of angiotensin II. The following is responsible for narrowing the blood vessels. The body starts to work even harder, and hence, the overall blood pressure rises. Captopril has been a prevalent example of a successful ACE inhibitor that is widely subscribed. Thiazides, another class of drug chemical is responsible for increasing urine production by the body. It works by pulling the NaCl and water into the lumen. Some of the prevalent examples of thiazide salted drugs are indapamide and hydrochlorothiazide. Treating diabetes insipidus and renal tubular acidosis and decreasing the risk of kidney stones in those with a high calcium level in the urine are some of the additional benefits which are offered by the salts such as indapamide and hydrochlorothiazide. Organizations are revamping the drug combinations, and the combination of ACE inhibitors with thiazide receptors is recommended. Medical advancements in the field of drug discoveries along with the rising cases of heart attacks, heart failures, and hypertension are some of the identified factors driving the ACE Inhibitors with Thiazides Drugs industry forward in the projected period of 2022-2027.
ACE Inhibitors with Thiazides Drugs Market Segmentation Analysis- By Application
The ACE inhibitors with thiazides drugs market based on the application can be further segmented into Heart Failure, Diabetes, Hypertension, Heart Attack, and chronic kidney disease, and Others. Hypertension held a dominant market share in the year 2021. It is owing to two predominant reasons. For one, the following drug has been FDA-approved as a few medicines to treat high blood pressure. Secondly, the salat of ACE and thiazides works by tackling a single set of problems with multiple methods. Hence, the efficacy of the drug in treating high blood pressure rises multitudes.
Moreover, hypertension is estimated to be the fastest-growing, with a CAGR of 3.4% over the forecast period of 2022-2027. It is owing to a projected increase in the cases of high blood pressure in the younger population, especially the millennials. Moreover, as per the estimates, a region like Europe has high or around 60% prevalence of hypertension than the likes of Canada and the USA. Moreover, with growing urbanization, the sedentary lifestyle will push people to rely on unhealthy diets which in turn leads to obesity. Obesity has been linked as one of the prima facie in causing hypertension.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=19742
Report Price: $ 4500 (Single User License)
ACE Inhibitors with Thiazides Drugs Market Segmentation Analysis- By Distribution Channel
The ACE inhibitors with thiazides drugs market based on distribution channel can be further segmented into offline and online. The offline segment held a dominant share in the year 2021. It is owing to the prevalence of high blood pressure in countries lying in the low- and middle-income countries. As per WHO, around 1.28 billion people have the following condition. In which around two-thirds lie in the low-income countries. Countries such as them do not have a robust digital infrastructure, thereby making them resilient on offline channels.
However, the online segment is estimated to be the fastest-growing, with a CAGR of 3.5% over the forecast period of 2022-2027. It is owing to the growing digital inclusion of the predominant portions of the population. Additionally, the online marketers are now substantiating various resources onto their application which will facilitate- diagnosis, follow-up, and easy access to medications.
ACE Inhibitors with Thiazides Drugs Market Segmentation Analysis- By Geography
The ACE inhibitors with thiazides drugs market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 37% as compared to the other regions in 2021. It is owing to the presence of major drug manufacturers in the following demographic. Additionally, countries such as Canada have a prevalence of 25%, i.e., one in every four people has problems pertaining to hypertension. Owing to the following reason, the market held a dominant position.
However, Asia-Pacific is set to offer lucrative growth opportunities to marketers in the projected period of 2022-2027. It is owing to two predominant reasons. For one, the region is seeing a heightened urbanization trend, which has made the younger adults prone to hypertension. Secondly, as per OECD, a major proportion of the population will age at a steadfast pace by 2040. Hence, owing to a vast demand, the ACE inhibitors with thiazides market will exhibit phenomenal growth avenues.
ACE Inhibitors with Thiazides Drugs Market Drivers
The commonality of hypertension amongst older people has been a key driver for the market.
High blood pressure is extremely common in older adults, especially those above the age of 65+. A scientific reason for the same is that one’s vascular system changes and hence, the arteries get stiffer and tighter, thereby, increasing the blood pressure. As per the report of the US National Health and Nutrition Examination Survey, around 70% of the people consuming blood pressure-related medication are older than 65+. Moreover, the geriatric population is expected to increase multifold in the times to come. For example, as per the CDC estimates, around 77 million adults would be above 65+, which currently are close to 53 million. The following cases would need people to rely on the thiazides-based drugs, which are combined with ACE inhibitors.
The rising number of hypertension-related cases has started increasing in the younger adults/professionals which will further allow the market to grow.
Rising urbanization has resulted in people getting more and more jobs. However, a strong correlation exists between jobs and hypertension. For example, as per the survey by the Cardiological Society of India- CSI, around 20% of young adults have hypertension, which roughly translates to around 80 million people. Moreover, of the surveyed population only a quarter was on medication, of which around 50% had high and uncontrolled blood pressure. Further, people who were not under-medication were recorded to have out-of-control blood pressure. Again, the trends are not just limited to the Asian countries, they reflect elsewhere as well. As reported by CDC, 1.3 million youth aged between 12-19 have high blood pressure. Hence, the growing number of cases within this sub-segment will allow the market to grow multifold.
Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=19742
ACE Inhibitors with Thiazides Drugs Market Challenges
Contentions regarding the low efficacy of certain medications are the key factors hindering the growth of the market.
ACE inhibitors when used alone have not provided the researcher with concrete results about its efficacy, and they have regarded it as “less-effective with worse safety profiles.” Researchers further went on to compare both the line of treatments, which are-> by using ACE inhibitors or thiazide diuretics. The research took the sample space of 5million people and found that people who were prescribed taking the latter or thiazide diuretics had a 15% lower chance of having heart attacks or hospitalization for heart failure or strokes. Lastly, researchers said that if the people had used the latter form of treatment only, then the chance of having cardiovascular ailment would have been reduced by a significant margin. Ever since the following, people and scientific communities were left under turmoil to even have ACE inhibitors as the line of defense. The following contentions have been made public, people have gone wary and the market had resulted negatively from it.
ACE Inhibitors with Thiazides Drugs Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the ACE Inhibitors with Thiazides Drugs Market. The top 10- ACE Inhibitors with Thiazides Drugs Market companies include
Recent Developments
In October 2021, Lupin Pharmaceutical had to voluntarily withdraw its blood pressure medicine from the market. Certain dosages of irbesartan tablets and irbesartan and hydrochlorothiazide tablets. Both are used to treat hypertension or high blood pressure, and were distributed in 30- and 90-count bottles nationwide (USA). Moreover, the drug contains above the specification limit of impure-N-nitrosoirbesartan. The following compound is a carcinogen and has the potential to cause cancer in long run.
In August 2021, PD-Rx Pharmaceutical had to recall its 576 bottles of losartan potassium. The following is a combination drug containing ACE inhibitor and thiazide diuretics. It contained trace amounts of nitrosamine impurity NMBA, a carcinogen. FDA communicated that the use of the drug may cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.
In April 2021, a meta-analysis was done on a large proportion of the population afflicted with COVID-19. The analysis showed a lower risk of death, in patients who have had high levels of blood pressure. Additionally, cases of severe events reduce multifold, such as ventilation, intubation, or ICU were not needed with patients being treated with ACE inhibitors. Hence, the following research has paved way for the treatment of severe covid-19 cases
Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=19742
Key Takeaways
Relevant Titles
Pulmonary Hypertension Drug Market- Forecast (2022-2027)
https://www.industryarc.com/Research/Pulmonary-Hypertension-Drug-Market-Research-501992
Hypertension Drug Market- Forecast (2022-2027)
https://www.industryarc.com/Research/Hypertension-Drug-Market-Research-501786
For more Lifesciences and Healthcare related reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
For exclusive content regarding the latest trends in the world of Press Release distribution.
